Valeritas Holdings, Inc. (VLRX) Receives Consensus Rating of “Strong Buy” from Analysts

Shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price objective of $13.50 for the company and are expecting that the company will post ($1.69) EPS for the current quarter, according to Zacks. Zacks has also given Valeritas an industry rank of 176 out of 265 based on the ratings given to related companies.

Separately, ValuEngine upgraded shares of Valeritas from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.

An institutional investor recently bought a new position in Valeritas stock. C WorldWide Group Holding A S bought a new position in shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 233,952 shares of the company’s stock, valued at approximately $1,603,000. C WorldWide Group Holding A S owned 3.42% of Valeritas as of its most recent SEC filing. 5.74% of the stock is currently owned by institutional investors.

Shares of Valeritas (NASDAQ:VLRX) traded down $0.14 during mid-day trading on Wednesday, hitting $4.19. 8,021 shares of the stock traded hands, compared to its average volume of 30,643. The company has a current ratio of 3.88, a quick ratio of 3.20 and a debt-to-equity ratio of 3.54. Valeritas has a 52-week low of $2.00 and a 52-week high of $40.00.

TRADEMARK VIOLATION WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at

Valeritas Company Profile

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with's FREE daily email newsletter.

Leave a Reply